Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cognition Therapeutics, Inc. - Common Stock
(NQ:
CGTX
)
0.6354
-0.0479 (-7.01%)
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cognition Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
Today 6:00 EST
- Management conference call at 8:30 a.m. ET today -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
October 22, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
October 13, 2026
- An additional five years of patent protection may be possible through a standard extension -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
September 29, 2026
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
August 06, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
June 24, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
June 16, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 21, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 14, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 07, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
April 07, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics CEO Issues Letter to Shareholders
March 31, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
March 26, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
March 23, 2026
Conference Call and Live Webcast Scheduled for March 26, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
March 17, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
March 02, 2026
We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
February 05, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
January 27, 2026
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
January 06, 2026
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
December 03, 2025
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
December 01, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
November 13, 2025
Study conducted in collaboration with the Alzheimer’s Clinical Trials Consortium
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
November 06, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
September 02, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
August 27, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
August 12, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
August 07, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
July 29, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Power Metallic Mines (TSXV: PNPN | OTCQB: PNPNF) Issues Summer 2025 “BIG Picture” Exploration Update – More Stocks Inside
July 10, 2025
Via
AB Newswire
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
July 01, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
